BioStorage Technologies, a worldwide provider of long- and short-term storage of biomaterials, sample management and cold chain logistics, today announced its full-service biorepository near Frankfurt, Germany received green certification from ENTEGA Vertrieb GmbH & Co., a leading Germany-based sustainable energy supplier.
Serving global pharmaceutical and biotech firms, donor organizations and biobanks as well as research and academic organizations, BioStorage Technologies’ 18,000 square-foot (1,672 square-meter) biorepository, uses an estimated 360,000-kilowatt hours (kWh) of power per year. By using 100 percent renewable energy, BioStorage Technologies is preventing the generation of an estimated 189 tons of environmentally harmful carbon dioxide (CO2) in the first year, thus making a valuable contribution to environmental protection. As the European operation grows, the amount of carbon dioxide prevented from generation will increase significantly.
“We are pleased to have all of our global facilities operating with 100 percent renewable energy,” said F. John Mills, M.D., Ph.D., chairman and chief executive officer at BioStorage Technologies. “This initiative demonstrates our commitment to conserving energy and improving the health of the environment by decreasing carbon dioxide emissions.”
Dr. Wolfgang Höffer, managing director of BioStorage Technologies’ European operations, adds, “Using renewable energy is only one of the green initiatives underway at our facilities. Additional aspects of the initiative include environmentally conscious management of waste disposal, logistics, water consumption and paper use.” BioStorage Technologies is also researching low VOC (Volatile Organic Compound) cleaning agents, the use of fair-trade products where applicable and other ways of making facilities and services better for the overall health of individuals and the environment.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.